Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Fang, Ying  [Clear All Filters]
Journal Article
Li Y-R, Lyu Z, Tian Y, Fang Y, Zhu Y, Chen Y, Yang L. Advancements in CRISPR screens for the development of cancer immunotherapy strategies. Mol Ther Oncolytics. 2023;31:100733.
Shi J, Yu X, Li G, Zhao X, Chen J, Fang Y, Yang Y, Wang T, Xu T, Bian L, et al. DTL promotes head and neck squamous cell carcinoma progression by mediating the degradation of ARGLU1 to regulate the Notch signaling pathway. Int J Biol Macromol. 2024:129184.
Li Y-R, Fang Y, Lyu Z, Zhu Y, Yang L. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. J Transl Med. 2023;21(1):686.
Li Y-R, Zhou Y, Yu J, Kim YJeong, Li M, Lee D, Zhou K, Chen Y, Zhu Y, Wang Y-C, et al. Generation of allogeneic CAR-NKT cells from hematopoietic stem and progenitor cells using a clinically guided culture method. Nat Biotechnol. 2024.
Fang Y, Zhang M-C, He Y, Li C, Fang H, Xu P-P, Cheng S, Zhao Y, Feng Y, Liu Q, et al. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma. Signal Transduct Target Ther. 2023;8(1):381.
Li Y-R, Ochoa CJ, Zhu Y, Kramer A, Wilson M, Fang Y, Chen Y, Singh T, Di Bernardo G, Zhu E, et al. Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design. iScience. 2023;26(10):107952.
Ye P, Wu M, Cao J, Pei R, Yuan J, Zhuang H, Fang Y, Lu Y. Reduced-toxicity conditioning regimen with low dose post-transplantation cyclophosphamide and low-dose anti-thymocyte globulin as graft-versus-host disease prophylaxis for haploidentical stem cell transplantation in older patients. Ann Hematol. 2024.
Fang Y, Ye P-P. [Research Progress on the Application Strategies of Plerixafor in the Peripheral Blood Stem Cell Mobilization for Autologous Transplantation--Review]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2024;32(1):322-326.